$480 million Fort Myers biotech firm names interim CEO

NeoGenomics, a cancer-focused genetic testing services and oncology contract research firm, has named Lynn Tetrault, the current executive chair and principal executive officer, as board chair and interim CEO.

The move comes some six weeks after Mark Mallon, who had been CEO for just over a year, resigned in the wake of an underperforming earnings report. Tetrault was named executive chair after Mallon’s March 28 departure. She was also appointed to oversee the interim office of the CEO, according to a statement, “to provide seamless leadership continuity and operational management of the company while the board conducts a search for the company's permanent CEO.”